BACKGROUND: Drug users (DUs), a population that accounts for some of the fastest-growing human immunodeficiency virus (HIV) epidemics globally, lag behind other populations with regard to HIV-related outcomes. We evaluated the role of voucher incentives on linkage and retention in care among DUs in India. METHODS: In this randomized clinical trial, 120 DUs who were aged ≥18 years, HIV-infected, antiretroviral therapy (ART) naive, and ART eligible and who reported drug use in the prior month were randomized toincentive (INC) or control (CTL) conditions for 12 months. Participants randomized to the INC arm received incentives (redeemable for food/household goods) ranging in value from USD4 to USD8 for achieving prespecified targets (eg, ART initiation, visits to ART center). Subjects in the CTL group could win vouchers in prize-bowl drawings, but HIV care behaviors were not incentivized. The primary endpoint was time to ART initiation. RESULTS:Sixty participants each were randomized to the INC and CTL arms between December 2009 and September 2010. Participants in the INC arm were more likely to visit the government ART center (49 vs 33; P = .002); 27 participants in the INC and 16 participants in the CTL arm initiated ART (P = .04; hazard ratio for ART = 2.33 [95% confidence interval, 1.15-4.73]). Participants in the INC arm also had significantly more visits to the ART center (median number of visits, 8 vs 3.5; P = .005). However, no difference in viral suppression was observed. CONCLUSIONS: Modest voucher incentives improved linkage to and retention in HIV care, but did not significantly impact viral suppression among DUs in India, a disenfranchised and difficult-to-treat population. CLINICAL TRIALS REGISTRATION: NCT01031745.
RCT Entities:
BACKGROUND: Drug users (DUs), a population that accounts for some of the fastest-growing human immunodeficiency virus (HIV) epidemics globally, lag behind other populations with regard to HIV-related outcomes. We evaluated the role of voucher incentives on linkage and retention in care among DUs in India. METHODS: In this randomized clinical trial, 120 DUs who were aged ≥18 years, HIV-infected, antiretroviral therapy (ART) naive, and ART eligible and who reported drug use in the prior month were randomized to incentive (INC) or control (CTL) conditions for 12 months. Participants randomized to the INC arm received incentives (redeemable for food/household goods) ranging in value from USD4 to USD8 for achieving prespecified targets (eg, ART initiation, visits to ART center). Subjects in the CTL group could win vouchers in prize-bowl drawings, but HIV care behaviors were not incentivized. The primary endpoint was time to ART initiation. RESULTS: Sixty participants each were randomized to the INC and CTL arms between December 2009 and September 2010. Participants in the INC arm were more likely to visit the government ART center (49 vs 33; P = .002); 27 participants in the INC and 16 participants in the CTL arm initiated ART (P = .04; hazard ratio for ART = 2.33 [95% confidence interval, 1.15-4.73]). Participants in the INC arm also had significantly more visits to the ART center (median number of visits, 8 vs 3.5; P = .005). However, no difference in viral suppression was observed. CONCLUSIONS: Modest voucher incentives improved linkage to and retention in HIV care, but did not significantly impact viral suppression among DUs in India, a disenfranchised and difficult-to-treat population. CLINICAL TRIALS REGISTRATION: NCT01031745.
Authors: James L Sorensen; Nancy A Haug; Kevin L Delucchi; Valerie Gruber; Evan Kletter; Steven L Batki; Jacqueline P Tulsky; Paul Barnett; Sharon Hall Journal: Drug Alcohol Depend Date: 2006-10-23 Impact factor: 4.492
Authors: Sunil S Solomon; Monica Desai; A K Srikrishnan; Easter Thamburaj; C K Vasudevan; M Suresh Kumar; Suniti Solomon; David D Celentano; Shruti H Mehta Journal: Subst Use Misuse Date: 2010-02 Impact factor: 2.164
Authors: Sunil S Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam S Kumar; Suniti Solomon; Gregory M Lucas; Shruti H Mehta Journal: AIDS Date: 2009-05-15 Impact factor: 4.177
Authors: S S Solomon; C S Hawcroft; P Narasimhan; R Subbaraman; A K Srikrishnan; A J Cecelia; M Suresh Kumar; Suniti Solomon; J E Gallant; D D Celentano Journal: Indian J Med Res Date: 2008-05 Impact factor: 2.375
Authors: Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil Journal: J Subst Abuse Treat Date: 2016-06-24
Authors: Maxine L Stitzer; Alexis S Hammond; Tim Matheson; James L Sorensen; Daniel J Feaster; Rui Duan; Lauren Gooden; Carlos Del Rio; Lisa R Metsch Journal: AIDS Patient Care STDS Date: 2018-06-08 Impact factor: 5.078
Authors: Allison M McFall; Shruti H Mehta; Aylur K Srikrishnan; Gregory M Lucas; Canjeevaram K Vasudevan; David D Celentano; Muniratnam S Kumar; Suniti Solomon; Sunil S Solomon Journal: AIDS Care Date: 2016-04-07
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Maxine Stitzer; Moupali Das; Mamta K Jain; Allan E Rodriguez; Wendy S Armstrong; Gregory M Lucas; Ank E Nijhawan; Mari-Lynn Drainoni; Patricia Herrera; Pamela Vergara-Rodriguez; Jeffrey M Jacobson; Michael J Mugavero; Meg Sullivan; Eric S Daar; Deborah K McMahon; David C Ferris; Robert Lindblad; Paul VanVeldhuisen; Neal Oden; Pedro C Castellón; Susan Tross; Louise F Haynes; Antoine Douaihy; James L Sorensen; David S Metzger; Raul N Mandler; Grant N Colfax; Carlos del Rio Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Shruti H Mehta; Gregory M Lucas; Suniti Solomon; Aylur K Srikrishnan; Allison M McFall; Neeraj Dhingra; Paneerselvam Nandagopal; M Suresh Kumar; David D Celentano; Sunil S Solomon Journal: Clin Infect Dis Date: 2015-08-06 Impact factor: 9.079
Authors: Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman Journal: Drug Alcohol Depend Date: 2020-08-02 Impact factor: 4.492